Pacylex Pharmaceuticals Announces First Patient Dosed in a Phase 2a Study of PCLX-001 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
The first patient has been dosed with PCLX-001 monotherapy, a first-in-class, oral small molecule N-myristoyltransferase (NMT) inhibitor, in a Phase 2a expansion study.
The expansion study will enroll up to 20 patients.
Pacylex Pharmaceuticals Reports a Potential Drug Sensitivity Gene Signature and the Effects of Myristoylation Inhibition on Angiogenesis and Cancer Cell Migration at American Association of Cancer Research (AACR) 2023.
